<DOC>
	<DOCNO>NCT00662597</DOCNO>
	<brief_summary>The purpose study determine add ASA404 standard chemotherapy make cancer treatment effective patient advance lung cancer .</brief_summary>
	<brief_title>ASA404 Placebo Combination With Paclitaxel Carboplatin First-Line Treatment Stage IIIb/IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically confirm nonsmall cell carcinoma lung . ( Histological cytological specimen must collect via surgical biopsy , brushing , wash core needle aspiration define lesion . Sputum cytology acceptable . ) 2 . Newly diagnose Stage IIIb disease ( malignant pleural effusion pericardial effusion confirm cytologically ) Stage IV disease 3 . No prior systemic antineoplastic treatment Stage IIIb/IV nonsmall cell carcinoma lung ( Prior neoadjuvant adjuvant chemotherapy earlier stage I/II NSCLC allow 12 month prior Baseline visit . ) 4 . Age ≥ 18 year old 5. WHO Performance Status 01 6 . Measurable nonmeasurable disease per RECIST criterion ( Posttext supplement 1 ) 7 . Lab value within range , define , within 2 week randomization : Absolute neutrophils count ( ANC ) &gt; 2.0 x 109/L Platelets ≥ 100 x109/L Hemoglobin ≥ 10 g/dL Serum creatinine ≤ 1.5 x ULN ( ≤ 120 micro mol/L ) Serum bilirubin ≤ 1.5 x ULN ( ≤ 25 micro mol/L ) Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis ) International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤ 1.5 x IULN ( Sections 6.9.1 7.3.4.2 ) Electrolyte value ( potassium , calcium , magnesium ) within &gt; 1 x LLN &lt; 1 x ULN . Patients correct electrolyte value eligible . See Sections 6.8.1 7.3.4.3 . Females childbearing potential must negative serum pregnancy test ( confirmation negative urine pregnancy test within 72 hour prior initial dose ) . 8 . Life expectancy ≥ 12 week 9 . Written inform consent obtain accord local guideline 1 . Patients CNS metastasis ( Patients clinical sign CNS metastases must CT MRI brain perform rule CNS metastasis order eligible study participation . Patients brain metastasis surgically remove irradiated residual disease confirm image allowed. ) . 2 . Patients history another primary malignancy ≤ 5 year , exception nonmelanoma skin cancer cervical cancer situ . 3 . Radiotherapy ≤ 2 week prior randomization . Patients must recover radiotherapyrelated toxicity . 4 . Major surgery ≤ 4 week prior randomization minor surgery ≤ 2 week prior randomization . ( Major surgery define use general anesthesia however , endoscopic examination diagnostic intent consider major surgery . Insertion vascular access device exempt exclusion criterion . Patients must recover surgeryrelated complication . 5 . Concurrent use investigational agent patient receive investigational agent ≤ 4 week prior randomization 6 . Prior exposure TumorVDAs vascular target agent ( antiVEGF , antiVEGF receptor agent , antiEGFR agent [ bevacizumab , cetuximab , etc . ] ) 7 . Pleural effusion cause ≥ CTC grade 2 dyspnea 8 . Patients systolic BP &gt; 160 mm Hg and/or diastolic BP &gt; 90 mm Hg 9 . Patients recent hemoptysis associate NSCLC ( &gt; 1 teaspoon single episode within 4 week ) 10 . Patients one following : Patients long QT syndrome Patients Baseline 12lead ECG QTc &gt; 450 msec per central evaluation Congestive heart failure ( NY Heart Association class III IV ) Patients myocardial infarction within 12 month study entry Unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris History labile hypertension poor compliance antihypertensive regimen History sustain ventricular tachycardia Any history ventricular fibrillation Torsades de Pointes Right bundle branch block leave anterior hemiblock ( bifasicular block ) Bradycardia define heart rate &lt; 50 beat per minute 11 . Concomitant use drug risk cause Torsades de Pointes ( See Table 63 ) 12 . Known allergy hypersensitivity platinumcontaining drug , taxanes , drug formulate Cremophor EL ( polyoxyethylated castor oil ) known excipients drug . 13 . Peripheral sensory neuropathy functional impairment ( CTC grade 2 neuropathy , regardless causality ) 14 . Pregnant breast feeding female • Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/ml ) 15 . Women child bear potential sexually active male , unwilling unable use require highly effective method ( ) contraception sex receive treatment least 6 month discontinuation study treatment . ( Adequate form contraception include IUD , oral depot contraceptive barrier method plus spermicide . ) • Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction take paclitaxel therefore consider effective contraceptive method study use single agent . Therefore , highly recommended concomitant barrier method use oral , implantable , injectable contraceptive . The investigator shall counsel patient accordingly . Women childbearing potential must negative pregnancy test ( serum urine ) 72 hour prior administration study treatment . For list substrate human liver microsomal P450 enzyme , visit website ( http : //medicine.iupui.edu/flockhart/ ) 16 . Concurrent severe and/or uncontrolled medical disease ( i.e . uncontrolled diabetes , chronic renal disease , chronic liver disease , confirm diagnosis HIV infection active uncontrolled infection ) . 17 . Significant neurologic psychiatric disorder could compromise participation study Patient unwilling unable comply protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tumor vascular disrupting agent</keyword>
	<keyword>VDA</keyword>
	<keyword>ASA404</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>